In the current work, our goal was to minimize the uncertainty in the measurement of EYO in DS by directly linking the time estimates and tau burden to well-characterized Aβ PET data using the SILA algorithm[36] across participants from the Alzheimer’s Biomarker Consortium -Down Syndrome (ABC-DS) study[45]. The gene discussed is MAPT; the disease is Down syndrome.